FDA Inspection
PPD Development, L.P.PPD Development, L.P. – FDA Inspection, May 18, 2018
Record Details
This FDA Inspection record concerns PPD Development, L.P., with an inspection on May 18, 2018, issued by the Center for Drug Evaluation and Research, covering drugs.
- People
- Jonathan R. Campos (Issuing Officer)
- Mohsen Rajabi Abhari (Issuing Officer)
View Company Profile
ID · a09fb41c-bfb2-4bd5-9a29-33af8b2a7061
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1056412
- FDA center
- Human Drugs
- Project area
- Bioresearch Monitoring
- Outcome
- Form 483 issued
Other FDA inspections of PPD Development, L.P.
9| Date | Classification | Office | Project area |
|---|---|---|---|
| May 1, 2026 | Not classified | Minneapolis District Office | |
| September 25, 2025 | VAI | Minneapolis District Office | Drug Quality Assurance |
| April 5, 2023 | NAI | Minneapolis District Office | |
| July 16, 2021 | VAI | Center for Biologics Evaluation and Research | Human Cellular, Tissue, and Gene Therapies |
| September 19, 2019 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for PPD Development, L.P.
- FDA Inspection 1320960 - 2026-05-01
- FDA Inspection 1284012 - 2025-09-25
- FDA Inspection 1202015 - 2023-04-05
- FDA Inspection 1146503 - 2021-07-16
- FDA Inspection 1105196 - 2019-09-19
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.